This eXtract video features key information from the EULAR Congress of Rheumatology 2020 eCongress. This year’s conference released data on more treatment options for moderate-to-severe rheumatoid arthritis across an expanding list of drug classes, including a recently-approved selective oral JAK inhibitor. This quick tour with an expert focuses on results from SELECT-CHOICE and expanded data from SELECT-COMPARE— the only comparative trials for rheumatoid arthritis therapies presented at EULAR. This video will focus on the efficacy and safety of newer oral therapies in light of these new head-to-head trials and the latest options available to patients to individualize their therapy based on their own preferences.

Tyrosine kinase inhibitors (TKI) active against epidermal growth factor receptor (EGFR) are a standard of care in EGFR-mutated non-small cell lung cancer (NSCLC) patients with sensitizing EGFR mutations. With the introduction of first, second, and third generation TKIs, the role of TKIs has and continues to evolve. In this program, a brief history of TKIs in NSCLC will lead to a review of current strategies relative to clinical features of EGFR-mutated NSCLC. These will be discussed in the context of the recently released Canadian Consensus guidelines. The potential future directions in the treatment of EGFR-mutated NSCLC will be evaluated in relation to on-going studies.

This quick tour with an expert focuses on the prevention of venous thromboembolism (VTE) in patients with gynecologic malignancies, specific to the context of the COVID-19 pandemic. The engaging format is meant to highlight best clinical practices in regards to the use of thromboprophylaxis in higher risk patients.

This eXtract video features key information from the European Academy of Neurology (EAN) Virtual Congress. This quick tour with an expert focuses on the latest data from the EXPAND open-label extension trial and newly released substudies from the core trial. More specifically, this video will focus on the long-term 5-year safety and efficacy results including disability and cognitive outcomes as well as treatment effects on myelin and brain tissue structures such as thalamic atrophy and cortical grey matter loss.

Heart failure is a dynamic process. When the myocardium is damaged, it sets in motion a vicious cycle of remodeling that is partly driven by neurohormonal activation. In this program, the emphasis will be placed on the value of prompt initiation of guideline-recommended therapies in patients with reduced ejection fraction (HFrEF). The goal is to slow, halt, or reverse the process of remodeling to preserve pump efficiency as measured with left ventricular ejection fraction (LVEF). As outlined in this program, the progression of heart failure is best understood on a continuum of downward decline, arguing for urgent and early introduction of optimized therapy.

This eXtract video features key information from the European Academy of Neurology (EAN) Virtual Congress. This quick tour with an expert focuses on data presented on the latest studies regarding calcitonin gene-related peptide (CGRP) inhibitors. More specifically, this video will focus on the long-term safety and efficacy results from open-label extension studies, real-world evidence from the PERISCOPE study, and the relevance of these data in routine clinical practice.

This program will focus on the importance of understanding glycemic control in the context of cardiovascular risk management for T2DM. The role of DPP-4 inhibitors will be examined in the context of SGLT2 inhibitors for the treatment of T2DM in patients who are inadequately controlled on first-line metformin.

Novel oral anticoagulants, also known as non-vitamin K antagonist oral coagulants (NOACs) have been shown repeatedly in large trials to be effective for stroke prevention in patients with atrial fibrillation. Of the four NOACs available, three are direct Xa inhibitors and one is a direct thrombin inhibitor. Differences between these drugs, including their dosing schedule, the need to be dosed with food, and their relative dependence on the kidney for clearance are among factors relevant to individualized therapy. In this program, these differences will be outlined, along with other factors that maximize the role of anticoagulants for preventing stroke in patients with atrial fibrillation

Immunomodulating agents have a favourable long-term safety profile, making them an appropriate choice for both induction therapy and in strategies for de-escalation. Regardless of the treatment setting, patient satisfaction plays a critical role in compliance. This extract video will focus on guiding patients to a therapy they are most comfortable with, based on their perspective on potential benefits, risks, and convenience.

Before selecting a disease-modifying therapy, RRMS patients need to be well educated about their disease, goals of therapy and treatment options. This video features an expert’s opinion on how best to guide patients in selecting a high-efficacy RRMS treatment, based on their short-term and long-term goals as well as their risk tolerance.